How has been the historical performance of Emcure Pharma?

Answer:The historical performance of Emcure Pharma shows a consistent growth trajectory in net sales and profits over the past three years.

Breakdown:
Emcure Pharma's net sales increased from 5,985.81 Cr in Mar'23 to 6,658.25 Cr in Mar'24, and further to 7,896.00 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, reaching 7,896.00 Cr in Mar'25. The company's total expenditure also rose, from 4,804.63 Cr in Mar'23 to 6,421.62 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit, excluding other income, improved from 1,181.18 Cr in Mar'23 to 1,474.38 Cr in Mar'25, while profit before tax increased from 747.22 Cr to 971.35 Cr in the same period. Consequently, profit after tax rose from 561.85 Cr in Mar'23 to 707.47 Cr in Mar'25, reflecting a healthy PAT margin of 8.96% in Mar'25. The company's total assets grew from 6,573.40 Cr in Mar'23 to 8,121.73 Cr in Mar'25, alongside a reduction in total debt from 2,194.93 Cr to 666.53 Cr, showcasing improved financial stability. Cash flow from operating activities was 851.00 Cr in Mar'25, although the net cash outflow was -58.00 Cr, indicating challenges in cash management despite operational profitability. Overall, Emcure Pharma's financial performance demonstrates robust growth in sales and profitability, alongside a significant reduction in debt levels.